Back to Search
Start Over
Update upon efficacy and safety of TNF-α inhibitors
- Source :
- Expert opinion on drug safety. 11(1)
- Publication Year :
- 2011
-
Abstract
- The ongoing progresses in the knowledge of the pathogenic mechanisms of various immune-mediated and inflammatory diseases as well as the availability of innovative biotechnological approaches have led to the development of new drugs that add to conventional treatments. Among these, tumor necrosis factor (TNF)-α inhibitors, that is, infliximab, adalimumab, etanercept, golimumab and certolizumab pegol, are now available for clinical use. This editorial discusses the recent indications of TNF-α inhibitors, the pretreatment considerations, the reported adverse events and, finally, the recommendations for its use in pregnancy.
- Subjects :
- musculoskeletal diseases
Anti-Inflammatory Agents
Pharmacology
Bioinformatics
Etanercept
Adalimumab
medicine
Humans
Immunologic Factors
Pharmacology (medical)
Certolizumab pegol
Adverse effect
Inflammation
business.industry
Tumor Necrosis Factor-alpha
Antibodies, Monoclonal
General Medicine
humanities
Golimumab
Infliximab
Tnf α inhibitors
Immune System Diseases
Tumor necrosis factor alpha
Female
business
medicine.drug
Subjects
Details
- ISSN :
- 1744764X
- Volume :
- 11
- Issue :
- 1
- Database :
- OpenAIRE
- Journal :
- Expert opinion on drug safety
- Accession number :
- edsair.doi.dedup.....d71a3518aead7d15da00c1646c203932